800.850.4306
  • Facebook
  • Twitter
  • LinkedIn
  • Facebook
  • Twitter
  • LinkedIn
  • Insights
    • News
    • Media
    • Events
  • About Us
    • Who We Are
    • Biologics Leadership
    • Careers
  • Contact
Biologics by McKesson
  • Patients
  • Providers
    • Risk-Based Care
  • Biopharma
    • Oncology
    • Rare and Orphan Care
    • Risk-Based Care
  • Payers
  • How to Prescribe
Select Page

XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson

Jun 29, 2020 | Press Release

CARY, N.C., June 29, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO® (selinexor) for...

Brandon Tom Appointed New General Manager of Biologics by McKesson

Jun 22, 2020 | Press Release

CARY, N.C., June 22, 2020—Biologics by McKesson, an independent specialty pharmacy and patient services company specializing in oncology, rare diseases and other complex therapeutic areas, is pleased to announce that Brandon Tom, PharmD, was named its new general...

QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson

Jun 2, 2020 | Press Release

CARY, N.C., June 2, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCK™ (ripretinib) for the treatment of adult patients...

RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson

Jun 1, 2020 | Press Release

CARY, N.C., June 1—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMO™ (selpercatinib), the first drug approved by the U.S....

Recent Posts

  • FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
  • OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
  • TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
  • OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
  • Video Transcript: Risk-Based Care: Personalized care for better patient outcomes

Archives

Biologics by McKesson logo

11800 Weston Parkway
Cary, NC 27513
T. 800.850.4306

  

Legal
Privacy Notice
Terms of Use
Nondiscrimination Notice

For Patients
Privacy Practices (pdf)
Patient’s Rights (pdf)

Learn more about McKesson

URAC Specialty Pharmacy accreditation seal for Biologics exp 2026ACHC Accreditation logo ACHC Accredited Oncology Logo

NASP seal denoting Biologics as a proud corporate member

Home
Patients
Providers
Payers
Biopharma
News
Careers
About Us
Leadership
Contact
Resources
How to Prescribe

© 2023 McKesson Corporation. All Rights Reserved.